Keros Therapeutics (KROS) Payables (2019 - 2025)

Keros Therapeutics has reported Payables for 7 years, with the latest figure at $2.0 million in Q4 2025.

• For the quarter ending Q4 2025, Payables fell 57.26% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $2.0 million (down 57.26% YoY), and the FY2025 full-year result was $2.0 million, down 57.26% from the prior year.
• Payables for Q4 2025 stood at $2.0 million, down from $2.3 million in the prior quarter.
• The five-year high for Payables was $7.7 million in Q2 2022, with the low at $1.4 million in Q2 2021.
• Historically, Payables has averaged $4.1 million across 5 years, with a median of $4.0 million in 2023.
• Annual changes were most pronounced in 2021 — Payables plunged 71.72% — and 2022, when it surged 458.31%.
• Keros Therapeutics' Payables stood at $3.6 million in 2021, then declined by 8.4% to $3.3 million in 2022, then jumped by 63.22% to $5.4 million in 2023, then slipped by 15.56% to $4.6 million in 2024, then plunged by 57.26% to $2.0 million in 2025.
• The last three Payables figures came in at $2.0 million (Q4 2025), $2.3 million (Q3 2025), and $5.3 million (Q2 2025), per Business Quant data.